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Purpose of Article: In a previous pilot randomized controlled trial including 54 pregnant
women with depression, maternal mood improved after Cognitive Behavioural Therapy
(CBT) compared to treatment as usual (TAU), showing medium to large effect sizes. The
effect persisted up to 9months postpartum, with infant outcomes also showingmedium to
large effects favoring CBT in various child domains. This perspective article summarizes the
results of a follow-up that was performed approximately 5 years later in the same cohort,
assessing the effects of antenatal Cognitive Behavioural Therapy for depression and
anxiety on child buccal cell DNA-methylation, brain morphology, behavior and cognition.
Findings: Children from the CBT group had overall lower DNA-methylation compared to
children from the TAU group. Mean DNA-methylation of all NR3C1 promoter-associated
probes did not differ significantly between the CBT and TAU groups. Children from the
CBT group had a thicker right lateral occipital cortex and lingual gyrus. In the CBT group,
Voxel-Based-Morphometry analysis identified one cluster showing increased gray matter
concentration in the right medial temporal lobe, and fixel-based analysis revealed reducedg February 2020 | Volume 11 | Article 341
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Frontiers in Psychiatry | www.frontiersin.orfiber-bundle-cross-section in the Fornix, the Optical Tract, and the Stria Terminalis. No
differences were observed in full-scale IQ or Total Problems Score. When the total of
hypotheses tests in this study was considered, differences in DNA-methylation and brain
measurements were no longer significant.
Summary: Our explorative findings suggest that antenatal depression treatment
decreases overall child DNA-methylation, increases cortical thickness, and decreases
white matter fiber-bundle cross-section in regions involved in cognitive function and the
stress response. Nevertheless, larger studies are warranted to confirm our preliminary
conclusion that CBT in pregnancy alters neurobiological outcomes in children. Clinical
relevance remains unclear as we found no effects of antenatal CBT on child behavior or
cognition (yet).Keywords: depression, anxiety, pregnancy, Cognitive Behavioural Therapy, neurodevelopment, programming, offspringINTRODUCTION
Antenatal depression occurs in approximately one out of 10
pregnant women (1–3). Pregnant women with depression are
less inclined to take good care of themselves, which is reflected by
poorer eating habits, more substance abuse and avoidance of
prenatal care (4). Also, antenatal depression is a predictor of
postnatal depression, which on itself is a detrimental condition
that is accompanied by many health risks for both mother and
child (5). Moreover, not only the woman herself is affected by the
disease, her unborn child may be also. Studies have shown that
children who were born to mothers affected by depression during
pregnancy were more often born prematurely and had lower
birth weights compared to children born to mothers without
depression in pregnancy (6, 7). Antenatal depression has also
been linked to poorer neonatal neurodevelopmental outcomes
such as state-regulation, habituation, regulatory behaviors and
sleep problems (8–10), a more difficult temperament in
childhood (11), and poorer cognition both in the neonatal
period (12) and in childhood (13). The evidence for an
association between antenatal depression and offspring
behavioral and emotional problems differs among studies, and
also seems dependent of the age when the child assessment took
place. Whereas one study showed that antenatal depression was
associated with both higher internalizing behavior and more
behavioral problems at the age of 3 (14), others did not report
such an association at the same age (15, 16). However, at the age
of 10, children who had been exposed to maternal depression in
utero, had higher scores on total emotional and behavioral
problems (17), and in cohorts of children aged 16, elevated
externalizing behavior (18, 19), and conduct problems (20) were
observed in those who were born to mothers with antenatal
depression. Also, in (pre)adolescence, a higher likelihood for
depression and anxiety symptomatology was seen in offspring
from mothers who were depressed when they were pregnant
(21–23). In some studies, the described associations between
antenatal depression and offspring neurodevelopment are
attenuated after postnatal maternal depressive symptoms are
taken into account (13, 15), whereas other studies that took intog 2account many important confounding do point to an
independent contribution of the antenatal period to offspring
neurodevelopmental disorders and psychopathology (24, 25).
During the past decade, the number of studies that carefully
address potential confounding factors has increased [reviewed by
Van den Bergh et al. (26)], with some studies also including
paternal symptoms of depression, to address the issue of genetic
inheritance of vulnerability to psychopathology (27). Another
study that also nicely demonstrated that effects of antenatal
depression on offspring development are (at least partly)
independent of genetic traits, is a study in which women
became pregnant by in vitro fertilization (IVF), either with
their own or through a donor oocyte, after which associations
between prenatal depressive symptoms and behavioral problems
in the children were analyzed. They showed that, although
associations with ADHD were observed only in genetically
related children, depression symptoms were related to conduct
disorder in both genetically related and unrelated children (28).
Several potential biological mechanisms have been suggested
to link maternal depression exposure in utero to an altered
offspring neurodevelopment. A frequently postulated
explanation is that as a result of the depressive state in a
pregnant woman, cortisol levels increase through chronic
activation of the hypothalamic–pituitary–adrenal (HPA) axis,
which then crosses the placental barrier and negatively affects
fetal brain development, which has clearly been shown in animal
studies (29, 30). However, evidence on associations between
depression during pregnancy and cortisol values in humans
have been inconsistent, suggesting the involvement of more
complex or additional underlying mechanisms that are
simultaneously activated in the mother, as a result of the
depression (31). Physiological systems that may be involved in
linking maternal depression to fetal neurodevelopment besides
the neuroendocrine system (HPA-axis), are the autonomic
nervous system (32), the cardiovascular system (33, 34) and
the immune system (35–37). As a consequence of the alterations
in maternal biochemical processes described above, fetal (neuro)
development may be altered. On a cellular level, epigenetic
alterations of fetal DNA may occur, potentially leading toFebruary 2020 | Volume 11 | Article 34
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differences in phenotype. Studies in humans have shown that
antenatal depression is associated with differential methylation of
offspr ing genes invo lved in neurodeve lopment or
psychopathology, with the glucocorticoid receptor gene
(NR3C1) showing the most consistent result of increased
methylation after prenatal maternal depression exposure (38–
41). The glucocorticoid receptor (GR) plays a pivotal role in the
negative feedback loop of the HPA-axis, eventually dampening
the stress response and cortisol release. Hence, HPA-axis
sensitivity and stress responsivity may be permanently altered
by prenatal depression through increased fetal NR3C1
methylation and lower GR density, which eventually may lead
to a heightened susceptibility for psychopathology such as
depression and anxiety. Brain regions that are known to be
involved in psychopathology and neurodevelopment include the
amygdala, hippocampus, and cortical structures located
primarily in the (pre)frontal and medial lobe. Morphological
characteristics of the brain in children visualized with MRI
techniques have been shown to be associated with prenatal
exposure to depression. For example, thinner frontal and
medial cortices and larger amygdala’s have been observed in
children from mothers who had higher symptoms of depression
in pregnancy compared to children from non-depressed mothers
(42, 43). Besides the volume and shape of the brain, the way the
brain is ‘wired’ may also be affected by in utero exposure to
maternal depression, through altered development, migration or
maturation of neuronal axons resulting in adverse connectivity
patterns or functionality between brain regions. Studies have
observed greater functional connectivity of mainly the amygdala
with surrounding brain regions in children who had been
exposed to increased maternal depressive symptomatology
before birth (44, 45). Also, a higher mean white matter
diffusivity, roughly reflecting a decrease in white matter
integrity, of the uncinated fasciculus and the cingulum bundle
has been described in children after prenatal exposure to
maternal depression, although the latter was attenuated by
paternal prenatal depressive symptoms (46).
The evidence from longitudinal studies on child neurobiological
outcomes after prenatal exposure to maternal depression suggests a
direct independent contribution of the antenatal period to child
neurodevelopment. However, confounding due to genetic
influences or other inherent maternal traits that are associated
with both depression and child neurodevelopment, are
challenging, if not impossible, to consider. The only way to
reliably establish causality, is by performing randomized
controlled trials (RCT) (47, 48). Nevertheless, experimental study
designs in humans are difficult, as depression is a non-random event
and cannot be ‘forced' upon someone. However, it is possible to
assess whether a reduction in depression symptoms in pregnancy, as
a result of a randomly allocated treatment in a group of depressed
pregnant women, leads to changes in the assumed neurobiological
systems in the desired directions, as well as to improvements in
neurodevelopmental outcomes in children, thereby providing more
conclusive evidence on the effects of (untreated) depression on
child neurodevelopment.Frontiers in Psychiatry | www.frontiersin.org 3To address this pivotal gap in research, the Beating the Blues
before Birth cohort study was developed at the Parent Infant
Research Institute in Melbourne, Australia. A pregnancy-adjusted
Cognitive Behavioral Therapy (CBT) for depression and anxiety
during pregnancy was developed and assessed in a feasibility study
and pilot randomized controlled trial (49). The program consisted
of seven individual sessions of CBT and one session in which the
partner was included. Women aged 18 years or older, less than 30
weeks pregnant, and with a depressive disorder were included.
Recruitment of women occurred via screening programs at the
Northern Hospital and Mercy hospital for women, as well as via
various health services and professionals, and the private sector, to
which the program was advertised widely. If a woman was
suspected for a clinical depression and met inclusion criteria, the
Edinburgh Postnatal Depression Scale [EPDS; (50)] was conducted,
and if the woman scored 13 points or higher on the scale, she was
asked for her consent to participate in the study. Women who
consented were referred to a psychologist to participate in a
Structured Clinical Interview (51), according to DSM-IV criteria
to yield a diagnosis of minor or major depression, or adjustment
disorder with mixed depression and anxiety (52). Concurrent major
psychiatric disorders, comorbid axis I disorders or medical
conditions that were likely to interfere with study participation,
risk requiring crisis management in case of very severe symptoms
and suicidal ideation, participation in other psychological programs
and significant difficulty with English were the exclusion criteria.
Symptom severity of depression and anxiety wasmeasured by use of
the Beck Depression (BDI-II) and Anxiety (BAI) Inventories, both
21-item clinical instruments with well-established psychometric
properties (53, 54). The distributions of the different types of
depression were: major depression 72%, minor depression 9%,
adjustment disorder 19%. Women were randomized to receive
CBT or Treatment as Usual (TAU). TAU meant that women
were either referred to their GP for further evaluation and
management or that they would be case managed by their
midwife, as would usually have happened in routine practice. The
BDI-II and BAI were assessed before randomization, 9 weeks after
randomization and again at 9 months postpartum. Following the
program, substantial improvements in depression and anxiety
symptoms in favor of the CBT group were observed. Depression
symptoms (BDI-II) dropped, on average, from the ‘severe’ range
(BDI-II = 30.07) to the ‘minimal’ range (BDI-II = 12.81) in the
CBT group, whereas the drop in the TAU group was more modest
(‘Cohens’ d = 0.53, 95% CI = 0.26 to 0.79). On average, anxiety
symptoms decreased from the ‘moderate’ (BAI = 22.37) to the
‘mild’ range (BAI = 10.40) in the CBT group, but remained
relatively elevated in the TAU group (d = 0.67, 95% CI = 0.33 to
1.01) (49). At 9 months, treatment effects had maintained.
Moreover, infant assessment at 9 months postpartum showed
favorable outcomes on the ‘problem solving’ (d = 0.72, 95% CI =
0.36 to 1.08) and ‘communication’ (d = 0.53, 95% CI = 0.27 to 0.80)
domain in the Ages and Stages Questionnaires [ASQ; (55)], as well
as large effects favoring the CBT group on the subscales ‘recovery
from distress’ (d = 1.08, 95% CI = 0.54 to 1.62), ‘high intensity
pleasure’ (d = 0.83, 95% CI = 0.42 to 1.24) and ‘negative affectivity’
(d = 0.84, 95%CI = 0.42 to 1.26) on the Revised version of the InfantFebruary 2020 | Volume 11 | Article 34
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significant treatment effects were found on the Parenting Stress
Index, with lower scores on the ‘total score’ (d = 1.44, 95% CI = 0.41
to 2.46), ‘child domain’ (d = 0.96, 95% CI = 0.16 to 1.75) and
‘adaptability’ (d = 0.88, 95%CI = 0.10 to 1.64) subscales, indicating a
lower number of child characteristics that may contribute to overall
stress in parents in the CBT group. No effects of treatment onmotor
or cognitive development and behavioral problems were found at
the age of 2 (57).STUDY DESCRIPTION
Current Perspective Article
Approximately 5 years postpartum a follow-up study to the original
Beating the Blues before Birth trial was performed. In this study, we
evaluated neurobiological alterations including offspring DNA
methylation, morphological and microstructural brain properties,
as well as behavioral and cognitive performance in 5-year old
offspring of mothers participating in the original trial. Findings on
behavioral, cognitive, neurobiological and epigenetic outcomes have
all previously been reported on in separate publications. In the
present paper, we aim to (1) provide an overview of the most
important outcomes of the follow-up study, (2) place these findings
on different outcomes in a broader perspective, (3) reflect on
strengths and limitations, and (4) provide recommendations for
future studies on this clinically relevant topic of treating antenatal
depression and studying outcomes in the offspring.
Follow-Up At Five Years of Age
The childhood follow-up study was initiated in 2016, aiming to
study the effect of maternal antenatal CBT for depression on
offspring neurobiological, behavioral and cognitive outcomes. All
women who had participated in the original RCT with known
contact details were re-contacted and invited to participate in a
follow-up study of their children approximately 5 years
postpartum. Baseline characteristics of mothers at enrollment
and birth outcomes were retrieved from the original study files. A
questionnaire on current sociodemographic characteristics
(including maternal age, marital status, family income and
highest completed education of the mother, child age, gender,
gestational age and weight at birth) was completed by mothers.
Mothers also completed the BDI-II and BAI for current
symptoms of depression and anxiety. Children donated buccal
swabs for DNA extraction and DNA methylation profiling.
Differential DNA methylation was calculated (1) on a genome-
wide level, (2) on 16 a priori selected genes that had been studied
in association with prenatal exposure to maternal stress, and (3)
on the promoter-associated probes on NR3C1. We derived
measures of child brain gray matter density, volume and
cortical thickness and white matter tract fiber densities and
cross-sections from anatomical and diffusion weighted
Magnetic Resonance Image (MRI)-scans. Mothers additionally
completed the Child Behaviour Checklist [CBCL; (58)], and were
invited to visit the clinic for a cognitive assessment with their
child performed by a trained researcher by use of the WechslerFrontiers in Psychiatry | www.frontiersin.org 4Preschool and Primary Scale of Intelligence, third edition
[WPPSI-III; (59)].
Statistical Analyses
DNA methylation data was analyzed in statistical software
package ‘R’. Anatomical weighted brain MRI scans were
analyzed using statistical software packages Freesurfer and
SPSS IBM version 24 to analyze subcortical volumes and
cortex thicknesses, and Statistical Parametric Mapping (SPM)
to analyze Voxel Based Morphometry. Connectivity-Based Fixel
Enhancement was used to analyze diffusion-weighted images to
estimate fiber bundle orientation, fiber bundle cross-section and
fiber bundle density. Behavioral and cognitive data was analyzed
using SPSS IBM version 24. We compared all outcomes between
children from the CBT and the TAU group for effect sizes and
confidence intervals. The results are presented as explorative and
hypothesis-generating in view of the low numbers and thereby
low statistical power.RESULTS
Participants
Of the originally 54 participating women, 45 were located and
invited for participation. 24 families re-consented to the 5-year
follow-up, 12 from the CBT and 12 from the TAU group. Baseline
data was retrieved from all 24 mother–child pairs. Missing data
included post-treatment BDI-II and BAI scores of two women from
the TAU group. All 24 women completed a questionnaire on
current sociodemographic information and completed the CBCL.
Completed CBCL questionnaires were sent to us by mail by five
women who were unable to visit the clinic for an additional
cognitive assessment with their child. A total of 19 mothers and
their children visited the clinic, of which all children participated in
a cognitive assessment (WPPSI-III) (59). Twenty three mother–
child pairs participated in the study of DNA methylation profiles,
including all 19 who visited the clinic. An additional four mothers
consented to send a buccal swab from their child using a pre-paid
envelop sent to their homes. MR brain imaging was attempted in all
19 children who visited the clinic. The MRI data of three subjects
had to be excluded from the analysis, because of significant motion
artefacts, resulting in a total of 16mother–child pairs included in the
MRI study. Table 1 shows the baseline characteristics of all women
participating in the original trial, and those participating in
respectively the DNA methylation study, the MRI study, the
behavioral questionnaire and the cognitive assessment. We did
not perform statistical tests to assess baseline characteristic
differences according to the CONSORT statement (60). Women
who participated in any of the follow-up’s were on average older,
more often highly educated, and had somewhat lower depression
and anxiety symptoms scores, compared to the total sample from
the original trial.
DNA Methylation
Children from the CBT group had overall lower DNA
methylation compared to children from the TAU groupFebruary 2020 | Volume 11 | Article 34
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68% of the promoter-associated NR3C1 probes were less
methylated in the CBT group, mean DNA methylation of all
NR3C1 promoter-associated probes did not differ significantly
between the CBT and TAU groups (difference = 0.002%, 95%
CI = −0.010 to 0.011) (61).
Brain Morphometry and White Matter
Microstucture
Children from the CBT group had a thicker right lateral occipital
cortex (difference = 0.13 mm, 95%CI = 0.005 to 0.26) and lingual
gyrus (difference = 0.18 mm, 95%CI = 0.01 to 0.34). In the CBT
group, Voxel-Based Morphometry analysis identified one cluster
showing increased gray matter concentration in the right medial
temporal lobe at p <0.05 uncorrected, and fixel-based analysisFrontiers in Psychiatry | www.frontiersin.org 5revealed reduced fiber-bundle cross-section in the Fornix, the
Optical Tract, and the Stria Terminalis at p <0.01
uncorrected (62).
Behavior and Cognition
Wefoundno significantdifferences in full scale IQ (difference:−3.2
IQ points, 95%CI = −16.1 to 9.7) or Total Problems Score
(difference: −1.7 points, 95%CI = −30.5 to 27.1) between children
in the CBT and TAU groups (57).DISCUSSION
In this perspective article, we present a summary of findings from a
longitudinal study based on a pilot RCT investigating the effects ofTABLE 1 | Baseline characteristics of all participants in a trial evaluating an antenatal cognitive depression treatment on offspring neurobiological, behavioral and
cognitive outcomes.





































19.2 (9.0) 19.3 (7.1) 18.8 (9.7) 17.5 (6.4) 18.2 (9.0) 19.7 (6.9) 20.0 (9.0) 18.8 (7.4)






18.1 (8.5) 11.9 (9.8) 21.5 (5.9)
T2 level anxiety (BAI), mean (SD) 10.6 (7.6) 16.7
(11.8)
11.6 (9.9) 15.3 (7.1) 11.6
(10.9)
15.5 (8.0) 11.6 (9.9) 16.2 (7.2) 11.6
(10.4)
17.5 (6.6)




















11.3 (8.9) 10.3 (9.9) 10.2 (7.5) 11.3
(10.6)
T1 Maternal age in years, mean (SD) 32.9 (5.9) 31.0 (5.8) 33.7 (5.7) 33.6 (5.2) 33.3 (6.4) 34.3 (5.6) 33.7 (5.7) 33.3 (5.1) 33.7 (5.7) 35.8 (3.3)
T1 Gestational age in weeks, mean
(SD)
19.9 (7.7) 21.0 (6.0) 18.3 (7.2) 19.0 (5.5) 16.6 (7.2) 20.0 (5.1) 18.3 (7.2) 19.5 (5.5) 18.7 (7.3) 18.9 (5.3)
T1 Antidepressant use (%) 7.1 22.7 0 11.1 0 12.5 8.3 8.3 9.1 0
T1 Marital status (%)
–Married 57.7 65.2 72.7 60.0 62.5 62.5 77.8 63.3 75 50.5
–De Facto 34.6 21.7 18.2 30.0 25 25 11.1 27.3 12.5 37.5
–Separated 0 8.7 0 10.0 0 12.5 0 9.1 0 12.5
–Single 7.7 4.3 9.1 0 12.5 0 11.1 0 12.5 0
T1 Birth location (%)
–Australia 73.1 82.6 81.8 80.0 87.5 100 77.8 72.2 75 87.5
–Other 26.9 17.4 18.2 20.0 12.5 0 22.2 27.8 25 12.5
T1 Income (%)
–Up to $ 20,000 0 4.5 0 10.0 0 12.5 0 9.1 0 12.5
–$ 20,001–$ 40,000 8.0 22.7 9.1 20.0 12.5 12.5 11.1 18.2 12.5 25
–$ 40,001–$ 60,000 20.0 13.6 9.1 10.0 0 0 11.1 9.1 0 0
–$ 60,001–$ 80,000 28.0 27.3 36.4 20.0 37.5 25 33.3 27.3 37.5 25
–> $ 80,001 32.0 31.8 36.4 40.0 37.5 50 33.3 36.4 37.5 37.5
–Do not wish to divulge 12.0 0 9.1 0 12.5 0 11.1 0 12.5 0
T1 Highest level of education (%)
–Did not finish school 3.8 12.0 0 0 0 0 0 0 0 0
–High School 7.7 24.0 0 27.3 0 25 0 25 0 25
–Certificate Level/Apprenticeship 23.1 4.0 9.1 9.1 12.5 12.5 9.1 8.3 10 12.5
–Advanced Diploma 19.2 4.0 36.4 0 25 0 36.4 0 30 0
–Bachelor degree 11.5 24.0 0 18.2 0 25 0 16.7 0 25
–Graduate diploma/certificate 19.2 16.0 36.4 27.3 37.5 25 36.4 25.0 40 25
–Postgraduate Degree 15.4 16.0 18.2 18.2 25 12.5 18.2 25.0 20 12.5February 2020 | Volume 11CBT, Cognitive Behavioral Therapy (intervention); TAU, Treatment as Usual (control); SD, Standard Deviation; T1, At randomization; T2, 9 weeks post-randomization; BDI-II, Beck
Depression Inventory—second edition; BAI, Beck Anxiety Inventory.| Article 34
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mood, child behavior and cognition, and neurobiological outcomes
including brain morphology and DNA methylation in children at a
mean age of 5 years. Results from the DNA methylation analysis
revealed no robust widespread DNA methylation differences
between the CBT and the TAU group (61). However, the top
1,000 mostly differentially methylated CpG sites between the CBT
group and TAU group showed overall lower average methylation in
the CBT group. Among all candidate genes, an overall lower average
methylation level was observed in the CBT group as well, which was
not surprising regarding the overall lower wide-spread DNA
methylation levels in the CBT group. Concurrently, the majority
of promoter-associated probes across NR3C1 showed lower average
methylation in the CBT group compared to the TAU group. These
results point to a possible beneficial effect of treatment of depression
during pregnancy on DNA methylation overall and on candidate
genes that have been associated with prenatal exposure to maternal
stress, depression or anxiety, specifically, on the promoter region of
NR3C1. In earlier studies, DNAmethylation of the 1F region on the
promoter of NR3C1 showed increased methylation in children who
were born to mothers who were depressed during their pregnancy
(40, 63, 64). Increased methylation of CpG-rich areas in a promoter
region of a gene, changes the activity of the DNA segment, typically
by repressing its activity. Although Oberlander et al. did not
examine whether DNA methylation of NR3C1 was also associated
with NR3C1 gene expression, DNA methylation of NR3C1 was on
itself associated with increased stress responsiveness in 3-month-old
infants (40). Dysregulation of HPA axis activity might be one of the
basal mechanisms in developing certain mood disorders such as
depression or anxiety. The fact that our study results indicate that
CBT during pregnancy possibly decreases DNA methylation of the
promoter region of NR3C1, is therefore promising.
The analyses of brain grey matter structure, volume and
concentration and white matter connectivity yielded interesting
results as well. We found that in medial and occipital brain
regions, a number of voxels exhibited a trend towards a larger
concentration of grey matter in the children from the CBT group
compared to the TAU group (62). For the morphometric measures,
we had a specific interest in the amygdala, as this structure is
involved in emotional processing and stress-reactivity, and has been
shown to be larger in children who were prenatally exposed to
maternal depression. We hypothesized that in the CBT group
smaller volumes of the amygdala would be observed, however,
this was not the case. We also estimated and compared cortical
thickness of regional gyri and sulci that have been shown to be
thinner in children after prenatal depression or anxiety exposure.
We found that in most brain regions, with some to a degree that
statistical significance was reached, the cortex of the grey matter was
thicker in the CBT compared to the TAU group, also after
adjustment for relevant confounders. Finally, we also examined
white matter tractography, by comparing the density and cross-
section of white matter fixels. The most apparent finding was that
children from the CBT group had smaller cross-section of white
matter fiber bundles at a region which was correlated to the position
and shape of the Fornix, the Stria Terminalis and Optical tract,
which may indicate developmental differences of specific whiteFrontiers in Psychiatry | www.frontiersin.org 6matter microstructures involved in emotional and memory
processing and the stress response.
Although both the results from the DNA methylation study
as well as the majority of the results from the brain imaging study
were pointing in the direction we had hypothesized, none of the
results remained statistically significant after we considered the
number of hypotheses tested. This did not come as a surprise
however, given the very small numbers in the samples.
There were no robust differences in IQ scores between the
CBT and TAU group. Also, we could not detect any differences
in behavioral problem scores between both groups. In additional
sub-analyses, we did observe that the severity of symptoms of
depression or anxiety prior to allocation to either the CBT or the
TAU group was associated strongly with lower scores on the
cognitive scales, as well as increased scores of problematic
behaviors (57). This indicated that the detrimental effects of
depression and anxiety symptoms in pregnancy on clinical
outcomes in children were still present, despite treatment.
Women started treatment at a mean gestational age of around
19 weeks. Perhaps, an earlier intervention, during critical stages
of embryonic/fetal brain development, would have led to
stronger positive effects on neurodevelopmental outcomes in
the children in later life, but this is highly speculative.
The lack of robust statistically significant findings may be
attributable to a lack of power, as we were able to include only a
small sample of children from the pilot RCT. Therefore,
substantial larger studies are needed to investigate whether
more subtle effects of CBT on cognition and behavior may
occur. Also, attrition bias may have influenced the validity of
our results, as there was some evidence that women who
responded to the 5-year follow-up study had been less
depressed or anxious at the start of treatment, compared to the
overall original cohort, as well as the women that had responded
to the 2-year follow-up. This may have been a contributive factor
to the fact that the beneficial treatment effect that was evident at 9
months of age but less apparent at 2 years of age, was not present
anymore at 5 years of age.
Evidently, we cannot establish whether the neurobiological
trends associated with CBT that we observed in children at the
age of 5 years, were actually the result of treatment effects on DNA
methylation and brain development of the fetus in utero. It is likely
that the positive effect of CBT on maternal mood seen after
treatment and at 9 months postpartum has had an enduring
effect on maternal mood and potentially on mother–child
attachment and parenting skills postnatally, which on its turn
may have affected DNA methylation profiles and brain
development in the children in a positive manner. Nevertheless,
in the follow-up studies at 2 years as well as 5 years postpartum,
maternal symptoms of depression and anxiety were approximately
similar in both the CBT and TAU group. However, as we did not
assess parenting skills or included other variables that are indicative
of maternal behavior and mother–child attachment postpartum, we
cannot exclude the possibility that the trends that were seen in
neurobiological outcomes were in fact mediated by the postnatal
environment. Nonetheless, the opposite is also possible—the effects
on DNA methylation and brain development may have beenFebruary 2020 | Volume 11 | Article 34
Bleker et al. Antenatal CBT and Child Neurodevelopmentstronger immediately after birth, and may have worn off in the
subsequent years, which would explain why the effects observed
were overall small and non-significant. Hence, this would also
explain why at the age of 9 months’ large treatment effects were
observed on developmental outcomes, which could not be replicated at
2 and 5 years of age. However, the developmental assessments at 9
months and at 2 and 5 years old were not necessarily reflective of
similar underlying developmental processes. It is possible that certain
beneficial treatment effects on developmental outcomes were missed,
simply because we did not measure them. Also, the positive effects of
CBT in pregnancy on neurodevelopmental outcomes may only appear
at a later age. Longer term assessment of the children to monitor the
occurrence of psychopathology, and tomeasure cognition and behavior
in, for example, early adulthood would therefore be highly informative.
A limitation of the study is that we were not able to address all
potential biological mechanisms that may be involved in the
association between prenatal exposure to maternal depression and
adverse offspring neurodevelopment. For example, it would have
been insightful if we had included maternal cortisol values during
pregnancy, before and after treatment, as this would have provided
further evidence whether maternal cortisol in pregnancy reflects the
biochemical state of ‘being depressed or not’ and if this is potentially
modifiable by psychological treatment. However, evidence from
literature indicates that maternal depression in pregnancy is often
not correlated with cortisol (31). Alternatively, maternal depression
during pregnancy may increase DNA methylation of placental
HSD11B2, which leads to a decrease in expression of the enzyme
that deactivates active cortisol, thereby allowing more cortisol to
cross the utero-placental barrier and reach the fetal circulation.
However, evidence in humans supporting this is limited, at least for
depression alone (65, 66). Also, the immune system has been shown
to interact with cortisol metabolism, and (DNA methylation and
gene expression of) indices of the immune system function such as
lymphocytes have shown to act as mediating and/or moderating
factors in the associations between maternal depression in
pregnancy and altered child neurodevelopment (37, 67).
Therefore, it would have been valuable if we had been able to
analyze maternal blood samples as well as neonatal blood samples
and/or placental samples for inflammatory as well as
neuroendocrine parameters, besides DNA methylation statuses of
candidate genes of for example, leukocytes. The reason these
measures were not included in the original study design was
because the main purpose of the original study was to assess the
effects of CBT on depressive symptoms during pregnancy on the
mothers clinically and whether this also translated into more
beneficial infant development on the short-term. The study
protocol that focused on neurobiological underlying processes 5
year postpartum, providing themain results that are included in this
article, was designed 5 years’ post-partum, and therefore we were
not able to include these measures, which in retrospect, would have
been highly informative.
Also, we did not include cortisol as an infant outcome measure at
the follow-up at 5 years of age, as indicator of HPA axis functioning in
the children after prenatal CBT treatment. Evidence from literature
indicates that a single baseline cortisol value does not fully reflect
HPA axis functioning, due to its wide variation across the day.Frontiers in Psychiatry | www.frontiersin.org 7Multiple values across a day-span are preferred, to consider the
physiological variation in diurnal rhythm of the HPA-axis. Moreover,
cortisol reactivity measures in response to a stressor may possibly
predict later life health even better (68). Therefore, measuring cortisol
would have been of much added value in our sample, had we
performed a stress test with the children as well. However, research
has shown that many stressors do not actually elicit a measurable
HPA stress response in children. An extensive protocol such as the
well-established Trier Social Stress Test (TSST) would potentially
have elicited a robust stress response (69), but the children from our
cohort were around 5 years old and too young to undergo the TSST.
Also, the duration of the assessment procedure was around 3 to 4 h
already, after which the children were generally very tired, and
including a stress assessment would probably have led to resistance
in the children, or for the parents to refuse overall participation.
However, in accordance with the small but promising positive
treatment effects that were seen on DNA methylation of the
promoter region of the glucocorticoid receptor gene, it would be
very interesting to re-invite the children in adolescence, to participate
in a stress paradigm and measure concurrent cortisol values. A larger
RCT (N = 230) on the effect of antenatal CBT onmaternal depression
and anxiety during pregnancy and child neurodevelopment at age 2 is
currently running. An add-on study that aims to include neonatal
(blood spot/buccal swabs) and child neurobiological (cortisol in
saliva) measures is currently in progress.CONCLUSION
Our findings indicate that CBT for antenatal depression may
improve neurobiological outcomes in children, defined by
decreased DNA methylation of genes involved in stress regulation
and morphological brain changes in cortical areas associated with
cognition, and white matter tracts involved in the stress response.
However, results did not survive correction for multiple testing, and
we could not confirm any subsequent beneficial effects on behavior
and cognition (yet). A small sample size and possible attrition may
have contributed substantially to the lack of robust findings, and
larger studies are needed to make conclusive statements on whether
CBT during pregnancy may positively affect neurobiological and
neurodevelopmental outcomes in the offspring. Nevertheless, the
current study is, to the best of our knowledge, the first to explore
neurobiological outcomes in children in an RCT assessing a
psychological intervention for maternal depression in pregnancy,
and our results point to a possible positive effect on DNA
methylation and brain development, which justifies further
research in larger trials. A large RCT (N = 230) aiming to test the
effect of antenatal CBT for depression and anxiety on child
neurodevelopment is currently ongoing.ETHICS STATEMENT
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